NCT02953093

Study of Acarbose in Longevity

Study of Changes in Muscle and Fat Gene Transcription With Acarbose Treatment: a Crossover Study

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Montefiore Medical Center · Academic / Other
• Sex: Male
• Age: 60 Years – 100 Years
• Healthy volunteers: Accepted

Summary

The investigators are studying the effects of acarbose on muscle and adipose gene transcription in older adults.

Detailed description

Acarbose, an FDA approved drug for the treatment of type 2 diabetes, has known effects on glucose metabolism. Evidence from mice indicates that acarbose may prolong lifespan. In humans, acarbose improves inflammatory markers and reduces cardiovascular events. Consequently, acarbose is of interest in clinical translational aging research since it may influence fundamental processes that contribute to age-related diseases. The study described herein is an exploratory study to examine the effect of acarbose treatment on the biology of aging in humans. Specifically, the investigators plan to study whether treatment with a 10 week course of acarbose will alter the gene expression profile in adipose tissue and muscle in older adults in pathways that are known to be affected by human aging, in a placebo-controlled crossover study.

Conditions

• Aging

Interventions

Type	Name	Description
DRUG	Acarbose	see arm description
OTHER	Placebo	See arm description

Timeline

• Start date: 2017-08-30
• Primary completion: 2019-04-20
• Completion: 2019-12-26
• First posted: 2016-11-02
• Last updated: 2025-06-24
• Results posted: 2025-06-24

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study